{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T02:16:16Z","timestamp":1777947376733,"version":"3.51.4"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP20K08821"],"award-info":[{"award-number":["JP20K08821"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20fk0108133"],"award-info":[{"award-number":["JP20fk0108133"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP22fk0108560"],"award-info":[{"award-number":["JP22fk0108560"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anaerobe"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.anaerobe.2025.102992","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T15:43:53Z","timestamp":1756914233000},"page":"102992","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["In vivo efficacy of fidaxomicin against rpoB mutant Clostridioides difficile infection"],"prefix":"10.1016","volume":"95","author":[{"given":"Mai Thu","family":"Hoai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaro","family":"Hitomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3827-6411","authenticated-orcid":false,"given":"Yoshitomo","family":"Morinaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.anaerobe.2025.102992_bib1","doi-asserted-by":"crossref","DOI":"10.1080\/21505594.2022.2150452","article-title":"Pathogenicity and virulence of Clostridioides difficile","volume":"14","author":"Buddle","year":"2023","journal-title":"Virulence"},{"key":"10.1016\/j.anaerobe.2025.102992_bib2","first-page":"723","article-title":"The role of toxins in Clostridium difficile infection","volume":"41","author":"Chandrasekaran","year":"2017","journal-title":"FEMS (Fed. Eur. Microbiol. Soc.) Microbiol. Rev."},{"key":"10.1016\/j.anaerobe.2025.102992_bib3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/jac\/dkac404","article-title":"Management of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA\/SHEA, ESCMID and ASID guidelines","volume":"78","author":"Bishop","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.anaerobe.2025.102992_bib4","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.mib.2011.07.030","article-title":"New target for inhibition of bacterial RNA polymerase: \u201cSwitch region.\u201d","volume":"14","author":"Srivastava","year":"2011","journal-title":"Curr. Opin. Microbiol."},{"key":"10.1016\/j.anaerobe.2025.102992_bib5","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1093\/cid\/cis358","article-title":"Fidaxomicin is an inhibitor of the initiation of bacterial RNA synthesis","volume":"55","author":"Artsimovitch","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.anaerobe.2025.102992_bib6","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1093\/cid\/ciaf028","article-title":"Emergence and spread of Clostridioides difficile isolates with reduced fidaxomicin susceptibility in an acute care hospital","volume":"80","author":"Redmond","year":"2025","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.anaerobe.2025.102992_bib7","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/jac\/dkad194","article-title":"In vivo emergence of a still uncommon resistance to fidaxomicin in the urgent antimicrobial resistance threat Clostridioides difficile","volume":"78","author":"Marchandin","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.anaerobe.2025.102992_bib8","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1093\/jac\/dkab231","article-title":"Mechanisms of antibiotic resistance of Clostridioides difficile","volume":"76","author":"Wickramage","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.anaerobe.2025.102992_bib9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/jac\/dkt302","article-title":"In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin","volume":"69","author":"Leeds","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.anaerobe.2025.102992_bib10","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1128\/AAC.02572-13","article-title":"Comparative microbiological studies of transcription inhibitors fidaxomicin and the rifamycins in Clostridium difficile","volume":"58","author":"Babakhani","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.anaerobe.2025.102992_bib11","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/jac\/dkx486","article-title":"Characterization of the impact of rpoB mutations on the in vitro and in vivo competitive fitness of Clostridium difficile and susceptibility to fidaxomicin","volume":"73","author":"Kuehne","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.anaerobe.2025.102992_bib12","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1099\/jmm.0.029470-0","article-title":"Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile","volume":"60","author":"Babakhani","year":"2011","journal-title":"J. Med. Microbiol."},{"key":"10.1016\/j.anaerobe.2025.102992_bib13","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01259-19","article-title":"Antimicrobial susceptibility and molecular characterization using shole-genome sequencing of Clostridioides difficile collected in 82 hospitals in Japan between 2014 and 2016","volume":"63","author":"Aoki","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.anaerobe.2025.102992_bib14","series-title":"Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria","year":"2018"},{"key":"10.1016\/j.anaerobe.2025.102992_bib15","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1038\/ncomms4114","article-title":"Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection","volume":"5","author":"Theriot","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.anaerobe.2025.102992_bib16","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1128\/AAC.02590-15","article-title":"Effect of fidaxomicin versus vancomycin on susceptibility to intestinal colonization with vancomycin-resistant Enterococci and Klebsiella pneumoniae in mice","volume":"60","author":"Deshpande","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.anaerobe.2025.102992_bib17","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1186\/1471-2334-12-342","article-title":"Adenosine A2A receptor activation reduces recurrence and mortality from Clostridium difficile infection in mice following vancomycin treatment","volume":"12","author":"Li","year":"2012","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.anaerobe.2025.102992_bib18","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/jaoac\/94.2.618","article-title":"Clospore: a liquid medium for producing high titers of semi-purified spores of Clostridium difficile","volume":"94","author":"Peres","year":"2011","journal-title":"J. AOAC Int."},{"key":"10.1016\/j.anaerobe.2025.102992_bib19","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1093\/cid\/cis337","article-title":"Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection","volume":"55","author":"Sears","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.anaerobe.2025.102992_bib20","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1093\/cid\/cis339","article-title":"Antimicrobial activities of fidaxomicin","volume":"55","author":"Goldstein","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.anaerobe.2025.102992_bib21","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.cmi.2022.12.015","article-title":"Fecal pharmacokinetics\/pharmacodynamics characteristics of fidaxomicin and vancomycin against Clostridioides difficile infection elucidated by in vivo feces-based infectious evaluation models","volume":"29","author":"Tashiro","year":"2023","journal-title":"Clin. Microbiol. Infection"},{"key":"10.1016\/j.anaerobe.2025.102992_bib22","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/jac\/dky375","article-title":"Characterization of a clinical Clostridioides difficile isolate with markedly reduced fidaxomicin susceptibility and a V1143D mutation in rpoB","volume":"74","author":"Schwanbeck","year":"2019","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Anaerobe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1075996425000551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1075996425000551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T11:15:49Z","timestamp":1772882149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1075996425000551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":22,"alternative-id":["S1075996425000551"],"URL":"https:\/\/doi.org\/10.1016\/j.anaerobe.2025.102992","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.04.17.649461","asserted-by":"object"}]},"ISSN":["1075-9964"],"issn-type":[{"value":"1075-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vivo efficacy of fidaxomicin against rpoB mutant Clostridioides difficile infection","name":"articletitle","label":"Article Title"},{"value":"Anaerobe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anaerobe.2025.102992","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102992"}}